Compliance Team supports Curium’s launch of generic version of DaTscan

Compliance Team is proud to announce that its support of Curium’s process equipment and facility qualifications helped ensure the FDA approved the company’s generic version of DaTscan.

The product, which is used in the diagnosis of Parkinson’s disease, will now be available at a lower cost to patients and healthcare providers.

Over the past decade, there has been an increase in the diagnosis of Parkinson’s disease, which has led to a demand for better and more affordable treatment options.

Curium’s generic Ioflupane I 123 Injection is a reliable and cost-effective option that will help patients receive the treatment they need.

Compliance Team, led by VP of CQV Services, Brian VanBibber worked with Curium throughout this project to ensure that the company’s process equipment and facility met FDA regulations.

Thanks to the team’s validation efforts, the manufacturing process for this product is now fully qualified and ready for production.  “It is exciting and rewarding for all those involved to see the hard work that went into this project, help make a difference in the lives of those who need it most,” states VanBibber.

Compliance Team has long been a leader in providing quality solutions for the life sciences industry, and this latest success is further proof of that commitment.

For more information on this project: https://www.curiumpharma.com/2022/04/05/curium-announces-fda-approval-of-a-generic-version-of-datscan-ioflupane-i-123-injection-in-the-u-s/